Sanofi beefs up can­cer drug pipeline, pay­ing cash hun­gry Im­muno­Gen $30M for full rights to on­col­o­gy port­fo­lio

Sanofi $SNY is once again re­jig­ging its part­ner­ship with Im­muno­Gen $IMGN. But two years af­ter punt­ing a can­cer drug as the phar­ma gi­ant over­hauled its can­cer drug pipeline, Sanofi is pay­ing $30 mil­lion in cash to grab added com­mer­cial­iza­tion rights for a string of on­col­o­gy as­sets — in­clud­ing a late-stage drug — as Im­muno­Gen builds up its cache of cash for its lead pro­gram.

At the top of the list is isat­ux­imab (SAR650984), an an­ti-CD38 an­ti­body in Phase III for mul­ti­ple myelo­ma. Then there’s SAR566658, an an­ti­body-drug con­ju­gate tar­get­ing CA6 in Phase II de­vel­op­ment for triple neg­a­tive breast can­cer; SAR408701, an an­ti-CEA­CAM5 ADC stud­ied for the treat­ment of sol­id tu­mors; “and an ad­di­tion­al ADC di­rect­ed to an undis­closed tar­get.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER